Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection, has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series B+ financing round. The round was led by Fortune Capital, with additional investments from Tao Capital, Hotgen Biotech, and the company’s management team. The funds will be directed towards clinical filing and marketing for Oriomics’ early screening products for liver cancer and digestive tract multiple cancers, which are based on a PCR+protein multi-omics platform. The proceeds will also support the research and development of other early screening and early diagnosis products.
Oriomics’ Technology and Market Expansion
Founded in 2018, Oriomics has established a complete set of effective site screening and ctDNA efficient enrichment technologies targeting the PCR platform. The company’s focus on early screening and diagnosis of cancers, particularly liver and digestive tract cancers, positions it at the forefront of precision medicine. The introduction of Hotgen as a strategic investor in late 2021, which owns China’s first liver cancer triple test product, further strengthens Oriomics’ market position and technological capabilities.
Investment in Innovation and Growth
The Series B+ financing round will enable Oriomics to accelerate its clinical filing processes and expand its marketing efforts for its innovative cancer screening products. With the backing of a strong investor base, Oriomics is well-poised to advance its mission to provide early and accurate cancer detection solutions, potentially improving patient outcomes and reducing the burden of cancer on individuals and healthcare systems.-Fineline Info & Tech
